Trial Profile
Randomized, Double-blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing of VERU-944 to Ameliorate the Vasomotor Symptoms Resulting From ADT in Men With Advanced Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2021
Price :
$35
*
At a glance
- Drugs Zuclomifene (Primary)
- Indications Hot flashes
- Focus Therapeutic Use
- Sponsors Veru Healthcare
- 01 Dec 2020 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Planned End Date changed from 30 Sep 2020 to 30 Oct 2020.
- 26 Aug 2020 Planned End Date changed from 30 Jul 2020 to 30 Sep 2020.